Ascentage Pharma Group International (AAPG) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending September 2025, Ascentage Pharma Group International (NASDAQ:AAPG) is held by 14 institutional firms.

• The percentage of Ascentage Pharma Group International owned by institutions changed from 0.0% in June 2025 to 0.0% in September 2025, marking a slight up trend.
• Quarterly data indicates a 42.81% shift in institutional share volume, and the annual owner count reflects an unavailable change.
• During the quarter, 9 institutions bought more Ascentage Pharma Group International shares, 4 sold shares, and 1 of the 14 total investors held their position steady.
• This class of investors increased its holdings in Ascentage Pharma Group International to 94.08K shares for the 13F-cycle ending September 2025, up by 28.20K shares quarter on quarter, and down N/A shares year over year.
• UBS Group AG's holding of 18.34K shares as of September 30, 2025 makes it the primary institutional investor in Ascentage Pharma Group International, owning 0.01% of the stock.
• Among the most significant buyers of Ascentage Pharma Group International during September 2025 were XY Capital Ltd (12.53K), UBS Group AG (10.99K), CITADEL ADVISORS LLC (9.65K), ABC ARBITRAGE SA (5.23K), Mirae Asset Global Investments Co., Ltd. (2.46K).
• Leading sellers of Ascentage Pharma Group International stock in September 2025 included NEOS Investment Management LLC (5.11K), TEMA ETFS LLC (5.11K), Point72 (DIFC) Ltd (2.96K), MORGAN STANLEY (753).
• The top 10 institutional holders of Ascentage Pharma Group International for the quarter ending September 2025 included UBS Group AG (18.34K), XY Capital Ltd (18.12K), Point72 (DIFC) Ltd (17.93K), NEOS Investment Management LLC (10.38K), TEMA ETFS LLC (10.38K), CITADEL ADVISORS LLC (9.65K), ABC ARBITRAGE SA (5.23K), Mirae Asset Global Investments Co., Ltd. (2.46K), Tower Research Capital LLC (TRC) (829), OSAIC HOLDINGS, INC. (220).